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ABSTRACT OF THE DOCTORAL PROJECT 
 
The Effects and Mechanisms of Phytochemicals on Alzheimer’s Disease Neuropathology 
by 
David M. Ross 
Doctor of Psychology, Graduate Program in Psychology 
Loma Linda University, September 2021 
Dr. Richard E Hartman, Chairperson 
 
Alzheimer’s disease effects millions of people, yet pharmacological treatments 
are limited. In the absence of effective treatments, identifying factors that can decrease 
the risk of developing Alzheimer’s disease is of significant interest. A growing body of 
epidemiological and experimental evidence suggests that dietary fruits and vegetables can 
have neuroprotective effects against the harmful effects of oxidative stress, 
neuroinflammation, and aging. These effects are mediated by various phytochemicals, 
which are compounds found in plants that can possess antioxidant, anti-inflammatory, 
and other beneficial properties. This review addresses epidemiological and experimental 
evidence for the effects and potential mechanisms of several commonly consumed 
phytochemicals on Alzheimer’s disease neuropathology and outcomes. The data suggest 
that regular consumption of bioactive phytochemicals from a variety of fruits and 






Phytochemicals are compounds produced by plants, some of which (e.g., phenols, 
terpenes, and organosulfurs) result in pigmentation, odors, and irritants that can protect 
the plant from internal (e.g., metabolic) insults like protein overexpression and free 
radical reactive oxygen species (ROS), and external (e.g., environmental) insults like 
predators, pathogens, ultraviolet radiation, and other threats to the plants’ survival. 
Consumption of plants that produce these phytochemicals seems to produce health 
benefits for humans mediated by modulating several biological pathways, including 
inflammatory processes, neuronal cell death (apoptosis), neurogenesis, 
neurotransmission, and enzyme function (Rossi, Mazzitelli, Arciello, Capo, & Rotilio, 
2008; M. Singh, Arseneault, Sanderson, Murthy, & Ramassamy, 2008). Many of these 
pathways have a direct effect on the development of Alzheimer’s disease (AD) and other 
types of age-related neuropathology. This review will provide a brief overview of AD 
etiology, followed by an outline of dietary phytochemicals that have been shown to affect 




ALZHEIMER’S DISEASE NEUROPATHOLOGY 
 
Recent prevalence rates suggest that over 5 million Americans currently have AD 
(Alzheimer’s Association, 2014), which is behaviorally characterized by a presentation of 
memory, motor, language, and executive dysfunction. The neuropathological markers of 
AD were originally thought to be limited to the formation of amyloid plaques 
surrounding neurons and the presence of neurofibrillary tangles (NFTs) of tau protein 
inside neurons. However, in recent years, the significance of mitochondrial dysfunction, 
neuroinflammation, astrogliosis, microglial activation, synaptic loss, neuronal damage, 
apoptosis, disruption of blood brain barrier (BBB) permeability, bacterial and viral 
infections, and intestinal microbiota have all been identified as significant contributors to 
AD neuropathology (Alonso et al., 2014; Bayer & Wirths, 2010; Block & Hong, 2005; 
Borgesius et al., 2011; Bredesen, 2009; Cherry, Olschowka, & O’Banion, 2014; Devi & 
Anandatheerthavarada, 2010; Houlden et al., 2016; Moreira, Carvalho, Zhu, Smith, & 
Perry, 2010; Rubio-Perez & Morillas-Ruiz, 2012; Schindowski, Leutner, Kressmann, 
Eckert, & Müller, 2001; Soscia et al., 2010; Terwel et al., 2011; Xue, Sparks, & Streit, 
2007; Yao et al., 2004; Zlokovic, 2008).   
Plaque accumulation has been identified in the medial temporal lobe, particularly 
the hippocampus and entorhinal cortex, prior to the emergence of behavioral symptoms. 
These structures have been implicated in learning and memory processes, which explains 
the cognitive impairments associated with AD. The extracellular plaques consist mainly 
of amyloid-beta (Aβ) peptides cleaved from larger amyloid precursor proteins (APP) by 
γ-secretase and β-secretase enzymes. The increasing concentration of extracellular Aβ 
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monomers gradually results in their polymerization into diffuse aggregates and eventually 
dense-core amyloid plaques (Wirths, Multhaup, & Bayer, 2004). Other proteins (e.g., 
apolipoproteins) and non-proteins (e.g., metals, hemes, and ROS) have also been found 
within the plaques (Dong et al., 2003; Mohsenzadegan & Mirshafiey, 2012; Roher, 
Palmer, Yurewicz, Ball, & Greenberg, 1993; Rosen et al., 2016). An age related increase 
in cortical and subcortical amyloid plaque levels is one of the most salient AD 
biomarkers (Victor L. Villemagne et al., 2011). NFTs, another prevalent AD biomarker, 
are damaged tau-based microtubules that disrupt intracellular transport mechanisms. 
Typically, these damaged neurons are found in areas with higher Aβ concentrations. 
Eventually, these damaged neurons are unable to function properly, leading to neuronal 
death. One current hypothesis for the etiology of AD is that the gradual accumulation of 
Aβ between the neurons initiates inflammatory and oxidative processes that lead to the 
formation of synaptic loss, NFTs, and neurodegeneration, particularly in neurons that use 
acetylcholine and glutamate (Palop & Mucke, 2010; Selkoe, 2002; Wirths et al., 2004). 
Aβ neurotoxicity has been demonstrated in hippocampal cell cultures (Reifert, 
Hartung-Cranston, & Feinstein, 2011), and the deleterious effects of Aβ deposition on 
synaptic functioning in the brain have been demonstrated using long-term potentiation 
(LTP), an in vitro model of learning and memory (Kimura, MacTavish, Yang, Westaway, 
& Jhamandas, 2012; Shipton et al., 2011; Walsh et al., 2002). Aβ has also been shown to 
induce hypersensitivity to excitotoxicity (i.e., damage caused by dysfunctional firing of 
glutamate) and oxidative stress in vitro (Matos, Augusto, Oliveira, & Agostinho, 2008; 
Nakayama et al., 2011). Furthermore, the formation of Aβ-heme peroxidase complexes 
within Aβ plaques begins a neuroinflammatory cascade leading to release of ROS and 
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damage to muscarinic acetylcholine receptors within the brain (Atamna, Frey, & Ko, 
2009; Fawcett et al., 2002). Importantly, these damaging effects can be ameliorated by 
dietary antioxidants (Kiko et al., 2012; Ono, Hamaguchi, Naiki, & Yamada, 2006; Peake, 
Suzuki, & Coombes, 2007). Although the accumulation of extracellular Aβ plaques is a 
prominent feature of the AD brain, synaptic loss within and surrounding the plaques may 
be a better predictor of the cognitive dysfunction seen in AD than the total amount of Aβ 
plaque deposition (Giannakopoulos et al., 2003; Schmitz et al., 2004). Individuals may be 
biologically more or less susceptible to neuronal buildup of Aβ, which may explain why 
the overall Aβ plaque burden is generally not a direct indicator of AD symptom severity 
(Tosun et al., 2011; V L Villemagne et al., 2013). 
Although it is currently unclear whether Aβ deposition is a primary cause of the 
neurodegeneration and behavioral deficits associated with AD, the gradual accumulation 
of Aβ in the brain appears to be associated with progressive oxidative stress and various 
harmful downstream effects. Oxidative stress associated with AD is believed to be partly 
responsible for damage to neuronal structures that contributes to functional deficits and 
ultimately neuronal death. Furthermore, experimental evidence suggests that 
manipulating levels of Aβ deposition in the brain can influence the emergence of 
behavioral deficits. 
For example, accelerated Aβ plaque accumulation tends to increase the risk of 
developing behavioral deficits associated with AD (i.e., learning and memory problems). 
Pathophysiological conditions that accelerate Aβ accumulation in the brain have been 
shown to increase the risk of developing AD. These conditions include Down syndrome, 
which is characterized by an overproduction of APP in the brain, leading to elevated Aβ 
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production and deposition. Individuals with Down syndrome are typically diagnosed with 
some form of dementia by approximately 50 years of age (Head et al., 2001; Netzer et al., 
2010; Schupf et al., 2007). Additionally, several inheritable mutations in the genes for 
APP or γ-secretase lead to elevated APP production and Aβ deposition in the brain and 
an earlier onset of AD (Bird, 2008; Cacace, Sleegers, & Van Broeckhoven, 2016; Krüger, 
Moilanen, Majamaa, & Remes, 2012). Identification of these genes has resulted in the 
development of transgenic rodent models of AD that express high levels of human APP 
and develop age-related neuropathology and cognitive deficits congruent with Aβ 
aggregation and deposition in the brain (Cohen et al., 2013; Hochgräfe, Sydow, & 
Mandelkow, 2013; Kitazawa, Medeiros, & M. LaFerla, 2012; Morrissette, Parachikova, 
Green, & LaFerla, 2009). Transgenic rodent models of AD focused on Aβ plaque 
development appear to mirror the behavioral hallmarks of AD seen in humans diagnosed 
with AD (Richard E. Hartman, Lee, Zipfel, & Wozniak, 2005). Additionally, in vivo 
imaging shows that Aβ plaques can aggregate rapidly in transgenic rodent brains, and that 
markers of neurodegeneration around these Aβ plaques develop quickly (Meyer-
Luehmann et al., 2008; Yan et al., 2009). Finally, neuroinflammatory processes and 
oxidative stress can induce accumulation of APP and Aβ in the brain, increasing the risk 
for developing AD. Common sources of these insults include traumatic brain injury, 
stroke, chronic low-level hypoxia (e.g., due to breathing problems), the “Western” diet 
(Abdul-Muneer, Chandra, & Haorah, 2015; Beer, Blacker, Hankey, & Puddey, 2011; 
Candore et al., 2010; Chamorro, Dirnagl, Urra, & Planas, 2016; Fernández-García, 
Cardona, & Tinahones, 2013; Iturriaga, Moya, & Del Rio, 2015; Jelic & Le Jemtel, 2008; 
Pistell et al., 2010; Pradeep, Diya, Shashikumar, & Rajanikant, 2012; Stranahan, Cutler, 
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Button, Telljohann, & Mattson, 2011; Q.-G. Zhang et al., 2012), and (importantly) the 
accumulation of Aβ. Oxidative stress is a common component of all brain injury and can 
induce further Aβ accumulation, initiating a harmful cycle of progressive oxidative and 
inflammatory load in the brain (Castellano et al., 2011; Jofre-Monseny, Minihane, & 
Rimbach, 2008). 
In addition to the observation that accelerating Aβ accumulation can increase the 
risk of developing AD and associated behavioral deficits, experiments with transgenic 
rodent models of Aβ plaque accumulation in the brain have shown that reducing Aβ 
levels in the brain can improve behavioral outcomes. These experiments include systemic 
treatments with monoclonal anti-Aβ antibodies and dietary manipulations that prevent, or 
in some cases reverse, the neuropathology and behavioral deficits associated with AD 
(Bernardo et al., 2009; Demattos et al., 2012; Richard E. Hartman, Lee, et al., 2005; 
Richard E Hartman et al., 2006; Joseph, Cole, Head, & Ingram, 2009; E. B. Lee et al., 
2006; Mark, 2010; Patten, Moller, Graham, Gil-Mohapel, & Christie, 2013; Pop et al., 
2010; Steele, Stuchbury, & Münch, 2007; A. Wang, Das, Switzer, Golde, & Jankowsky, 
2011; J. Wang et al., 2005). Reducing oxidative load in the brain is another pathway to 
improving cognitive function in Aβ transgenic rodent models without reducing Aβ levels 
(Kotilinek et al., 2008; Ongali et al., 2014; Tong, Lecrux, & Hamel, 2012). These 
findings suggest that Aβ contributes to the process of oxidative stress overload that 
gradually impacts the function of brain structures that mediate learning and memory. 
In summary, AD is associated with an abnormal buildup of Aβ plaques in the 
brain, which ultimately induces even greater Aβ accumulation in the brain. This “amyloid 
cascade” process creates a damaging cycle of neurodegenerative decline, including the 
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formation of NFTs, synaptic dysfunction and loss, excitotoxicity and apoptosis (A. 
Armstrong, 2014; Barage & Sonawane, 2015; Musiek & Holtzman, 2015; Pimplikar, 
2009). Current pharmacological approaches for treating AD have focused on stabilizing 
glutamatergic activity by blocking NMDA channels (e.g., memantine) and inhibiting 
acetylcholinesterase (AChE), an enzyme that breaks down acetylcholine and has been 
shown to induce Aβ aggregation (e.g., galantamine, tacrine, donepezil, and rivastigmine). 
NMDA antagonists can slightly slow the progression of AD symptoms and may reduce 
the susceptibility of neurons to excitotoxic degeneration. AChE inhibitors have been 
shown in animal experiments to slow AChE’s promotion of Aβ aggregation. 
Nevertheless, pharmacological treatments that target glutamate and acetylcholine have 
ultimately yielded disappointing results. Other experimental approaches that have yielded 
mixed results. Active and passive Aβ immunotherapies in transgenic mouse models of 
AD have yielded promising results, even in the absence of significant reductions in Aβ 
burden (Buttini et al., 2005; Richard E Hartman, Izumi, et al., 2005; Wilcock et al., 
2004). Human immunotherapy treatment has been more problematic, due to significant 
toxicity and tolerability concerns (Gilman et al., 2005; Lemere, Maier, Jiang, Peng, & 
Seabrook, 2006; Mangialasche, Solomon, Winblad, Mecocci, & Kivipelto, 2010; Schenk, 
Hagen, & Seubert, 2004; Siemers et al., 2010; Winblad et al., 2012). Although theses 
pharmacological failures have raised questions about the amyloid cascade hypothesis of 
AD, it has also been proposed that Aβ may initiate a multi-faceted pathogenic cascade 
that causes AD, rather than acting as the sole causative factor (A. Armstrong, 2014; 
Imtiaz, Tolppanen, Kivipelto, & Soininen, 2014; Salomone & Caraci, 2012). These 
downstream processes include tau aggregation, extracellular senile plaque formations, 
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mitochondrial dysfunction, neuroinflammatory processes, blood brain barrier (BBB) 
permeability disruption, and gut microbiome disturbances (Biron, Dickstein, Gopaul, 
Jefferies, & Hendey, 2011; Devi & Anandatheerthavarada, 2010; Hedskog et al., 2013; 
Miao et al., 2016; Moreira et al., 2010; Musiek & Holtzman, 2016; Narasingapa et al., 
2012; Rom et al., 2016; V. Singh et al., 2016; T. Yuan et al., 2016). Despite the lack of 
significant progress towards effective pharmacological interventions for AD, mounting 
epidemiological and experimental evidence indicates that diet and other sources of 
bioactive phytochemicals can significantly decrease the risk of developing AD 
neuropathology and symptoms by several potential mechanisms (Barnard et al., 2014; R 





PHYTOCHEMICALS AND ALZHEIMER’S DISEASE 
 
 A growing body of literature demonstrates that several bioactive phytochemical 
compounds, including vitamins (e.g. tocopherols and folic acid) and other organic 
compounds (e.g. phenols, terpenes, and organosulfurs) can affect aspects of the AD 
disease process. Potential mechanisms for these effects include antioxidant / anti-
inflammatory properties and modulation of Aβ concentrations and toxicity. Indeed, 
several pharmacological interventions of interest in AD stem from traditional herbal 
medicines. For example, the AChE inhibitor galantamine is derived from daffodil plants, 
and the anti-inflammation drug aspirin is derived from salicylic acid, a polyphenol found 
in the bark of willow trees. Both phytochemicals have garnered interest in the treatment 
of AD. Additionally, the role of the gut microbiome has been of increasing interest in 
studying the activity and mechanisms of dietary phytochemical compounds. 
Approximately 100 trillion diverse species of very metabolically active bacteria line the 
intestinal tract and have a strong influence (both pro- and anti-) on neuroinflammation, 
neuromodulation, and neurotransmission in the brain and periphery. The role of the 
potentially neurotoxic and proinflammatory microbial activations and their relationship to 
age-related amyloidogenesis and neurodegeneration are of increasing interest (Petra et al., 
2015; Y Zhao, Dua, & Lukiw, 2015). In addition to the gut’s role in the disease process 
of AD, its microbiome is also highly implicated in the bioavailability and bioactivation of 
dietary phytochemicals. It has been shown that 5-10% of dietary phytochemicals are 
absorbed initially. The remaining phytochemicals reach the colon, where they undergo 
extensive metabolizing by microbiota. Although the metabolic pathways and the 
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molecular targets are not well understood, the intestinal microbiome’s breakdown of 
dietary polyphenols may enhance their beneficial properties (H. Chen & Sang, 2014; 
Chiou et al., 2014; Gasperotti et al., 2015; Marín, Miguélez, Villar, & Lombó, 2015; 
Parkar, Trower, & Stevenson, 2013). Recent studies of the pharmacokinetic activity of 
several microbiome-produced polyphenol metabolites found that many of them reached 
the brain in statistically significant concentrations (Gasperotti et al., 2015; D. Wang et al., 
2015; T. Yuan et al., 2016). The following sections provide a survey of the 
epidemiological and experimental evidence for the effects of various plants, 
phytochemicals, and their metabolites on AD processes. 
 
Epidemiological Evidence 
Several studies have demonstrated that regular consumption of a variety of fruits 
and vegetables can decrease the risk for developing AD and slow its progression. For 
example, a large Swedish study collected dietary questionnaires from young adults 
approximately 40 years before regular cognitive screenings began in older age. It was 
found that higher fruit and vegetable consumption in earlier life was associated with a 
decreased risk of dementia and AD (Hughes et al., 2010). Similarly, a study of Irish 
adults, aged 64-93 years, found that consuming more fruits and vegetables was associated 
with significantly better overall cognitive functioning (Power et al., 2015). However, 
another study reported that consumption of dietary tocopherols (isoforms of vitamin E), 
vitamin C, P-carotene, and tea were not correlated with the risk of developing AD (Dai, 
Borenstein, Wu, Jackson, & Larson, 2006). 
Additionally, epidemiological evidence that isolated phytochemicals can affect 
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AD remains elusive. A study of older American adults to identify dementia incidence and 
AD diagnoses found that the use of vitamins C and E alone or in combination did not 
reduce AD or dementia incidence after a 5-year follow-up (Gray et al., 2008). Another 
study examining the effects of vitamin E supplementation in mild cognitive impairment 
(MCI) and AD found no evidence that it was beneficial (Farina, Isaac, Clark, Rusted, & 
Tabet, 2012). However, one study of older Chinese adults reported that lower α-
tocopherol levels were found in those diagnosed with MCI than in healthy controls (L. 
Yuan et al., 2016), and another recent study found that higher dietary intake of vitamins 
A, C, and E is associated with protection from AD (Berti et al., 2015). Nevertheless, the 
evidence suggests that acquiring vitamins through a varied diet of vitamin rich foods may 
provide more protection from AD than the use of vitamin supplementation. A recent 
study of elderly French adults examined the association between dietary vitamin B 
consumption and long-term incidence of dementia. Higher intake of dietary vitamin B 
reduced the risk of dementia with an approximately 50% lower risk for individuals 
consuming the highest amounts compared to the lowest consumers (Lefèvre-Arbogast et 
al., 2016). 
Furthermore, growing epidemiological evidence suggests that dietary omega-3 
fatty acids, most commonly found in flax, nuts, algae, and oil from fish that eat algae, 
may protect against developing AD (Burkholder-Cooley, Rajaram, Haddad, Fraser, & 
Jaceldo-Siegl, 2016; Perim Baldo et al., 2016; Robertson et al., 2016; Song et al., 2016; 
Tavakkoli-Kakhki et al., 2014). The so-called “Mediterranean” diet, which is 
characterized by regular consumption of foods with high fatty acid content from fish, 
nuts, and oils, has been of increasing interest, due to the growing body of evidence that it 
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is associated with several health benefits, including a reduced incidence of AD. 
Consumption of dietary fatty acids appears to explain a portion of the diet’s 
neuroprotective characteristics (Trichopoulou et al., 2014), and several epidemiological 
studies have demonstrated that diets supplemented with olive oil and/or nuts are 
associated with improved cognitive function in older adults (Perim Baldo et al., 2016; 
Sjögren et al., 2010; Valls-Pedret et al., 2015). 
Other sources of bioactive phytochemicals include colorful, flavorful, and 
aromatic spices. These spices often contain high concentrations of various phenols, 
terpenes, and organosulfurs. For example, a study of elderly adults showed that those 
whose diets included curry performed significantly better on neuropsychological tests of 
cognitive performance (Ng et al., 2006). This spice mix includes turmeric, a bright 
yellow root that contains a high concentration of the polyphenol curcumin. Light to 
moderate wine consumption has also been associated with a reduced risk for AD, 
although it remains unclear whether the effect is due to grape polyphenols (e.g., 
resveratrol) or ethanol (which itself is derived from plants) (Arntzen, Schirmer, 
Wilsgaard, & Mathiesen, 2010; Covas, Gambert, Fitó, & de la Torre, 2010; Orgogozo et 
al., 1997). 
Phytochemicals can also be consumed by other methods other than diet. For 
example, smoking tobacco was previously thought to possibly offer protection from Aβ 
deposition and the occurrence of AD. This was in large part due to postmortem 
examinations of the brains of AD that showed significantly lower levels of Aβ in the 
entorhinal cortex of smokers (Court et al., 2005). However, recent epidemiological 
studies have identified smoking as a risk factor for the development of AD (Norton, 
13 
Matthews, Barnes, Yaffe, & Brayne, 2014). A large community study of adults in the US 
found that older individuals who currently smoke are more likely to develop AD than 
those who never smoked. Given that experimental evidence of nicotine administered in 
animal models of AD suggests that nicotine may be neuroprotective (see section on 
nicotine), it appears likely that the act of smoking tobacco, rather than consumption of 
nicotine itself, increases the risk for developing AD, despite evidence of decreased 
postmortem Aβ in smoker’s brains. 
 In summary, epidemiological evidence suggests that consuming a wide variety of 
fruits and vegetables that contain high concentrations of bioactive phytochemical 
compounds may work collectively and synergistically to lower the risk for developing 
AD. Relatively few experimental clinical trials have been published assessing the effects 
of plant/phytochemical consumption on AD in humans. Several experimental preclinical 
studies using transgenic animals and/or in vitro models have provided evidence that 
various aspects of AD neuropathology can be manipulated by plants and their 
phytochemicals. The following subsections outline recent experimental literature 






Many plants produce polyphenols (large assemblies of phenols, which are 
molecules that contain an aromatic ring bonded to a hydroxyl group). These include 
common phytochemicals like the phenolic acids, stilbenoids, and flavonoids. 
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Phenolic Acids 
Several phenolic acids have been shown to modulate neuropathological pathways 
related to AD. For example, rosmarinic acid (derived from rosemary) and 
nordihydroguaiaretic acid (derived from creosote) have been shown to prevent and 
reverse Aβ aggregation in vitro (Farr et al., 2016; Lucarini et al., 2013; Rahman, Ansari, 
Rehman, Parvez, & Raisuddin, 2011). Additionally, coffee and tea are plants with 
relatively high concentrations of phenolic acids that possess antioxidant and anti-
inflammatory properties, such as caffeic acid and various tannins (Brezová, Šlebodová, & 
Staško, 2009; Esquivel & Jiménez, 2012; Ludwig et al., 2012; Vignoli, Bassoli, & 
Benassi, 2011). Coffee and tea are also discussed in the section on psychoactive alkaloids 
(caffeine), and tea is discussed in more detail in the section on flavonoids (flavans). 
Diets containing high amounts of the spice mixture curry have been associated 
with improved cognitive performance in elderly individuals (Braskie et al., 2011; Ng et 
al., 2006). Curcumin is a phenolic acid found in the curry spice turmeric, which is a 
bright yellow root related to ginger. It is structurally similar to thioflavine-S and Congo 
red, which are histological stains used to visualize amyloid fibrils in brain tissue. 
Interestingly, curcumin will also bind to amyloid fibrils in brain tissue sections and can 
be visualized under a fluorescent microscope to observe Aβ plaques (Reinke & 
Gestwicki, 2007; Ringman, Frautschy, Cole, Masterman, & Cummings, 2005). In 
addition to its Aβ binding properties in tissue sections, it has also been demonstrated to 
prevent and reverse Aβ aggregation in vitro (Ono, Hasegawa, Naiki, & Yamada, 2004; 
Yang et al., 2005). 
Experimentally, dietary curcumin has been reported to prevent oxidative stress, 
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synaptic damage, cortical microgliosis, and learning deficits in rats after 
intracerebroventricular infusion of Aβ (Frautschy et al., 2001). It also decreased Aβ 
plaques and oxidative stress in APP transgenic mice (G. P. Lim et al., 2001; Ono et al., 
2004; Yang et al., 2005) and reduced heme-Aβ peroxidase damage to muscarinic ACh 
receptors (Atamna et al., 2009). More recent studies with both rats and mice have 
examined whether curcumin attenuates inflammation and mitochondrial dysfunction in 
models of neurological insult. The results suggested that curcumin reduced post-insult 
lesion sizes and inflammatory biomarkers in the brain, and improved mitochondrial 
function and behavioral outcomes (Laird et al., 2010; Miao et al., 2016). Additionally, a 
transgenic mouse study demonstrated increased levels of DNA damage relative to control 
mice, and reported that dietary supplementation with curcumin significantly reduced the 
damage (Thomas et al., 2009). Its experimental effects are not limited to rodent models. 
A recent drosophila (fruit fly) experiment found that curcumin reduced oxidative stress 
and protected against age-related neurodegeneration (Seong et al., 2015), and a study of 
elderly humans after 12 weeks of curcumin supplementation demonstrated improved 
artery endothelial function by increased vascular nitric oxide bioavailability, reduced 
overall oxidative stress, and improved conduit artery endothelial function (Parker et al., 
2016). Curcumin also inhibits the pro-inflammatory cytokine nuclear transcription factor-
κβ (NF-κβ) (B. B. Aggarwal & Shishodia, 2004) and modulates other cell-signaling 
pathways (B. B. Aggarwal & Shishodia, 2006). Curcumin also possesses potent 
antimicrobial properties which may possibly have direct or indirect effects on Aβ 
aggregation or other neuropathological pathways to AD. An In vitro study of curcumin 
demonstrated that curcumin dose-dependently inhibits the formation of Aβ fibrils and 
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destabilizes already formed Aβ fibrils. However, the mechanism by which Curcumin 
inhibits Aβ fibril formation and Aβ fibril destabilization remains unclear and could be 
due to a synergistic effect of curcumin’s anti-aging and anti-microbial properties 
(Kumaraswamy, Sethuraman, & Krishnan, 2013; Ono et al., 2004; Rai, Singh, Roy, & 
Panda, 2008). 
The anti-amyloid and antioxidant activity of curcumin has generated great interest 
for the treatment of AD. However, the insolubility of curcumin in water has restricted its 
use. This restriction may be overcome by the synthesis of curcumin nanoparticles that 
maintain anti-oxidative properties, are non-cytotoxic, and can destroy amyloid 
aggregates, thus approaching the treatment of Alzheimer's disease from several angles. 
Pomegranates have been consumed as food and used medicinally for millennia and 
contain high concentrations of punicalagins, which break down in water to smaller 
phenolic acids such as ellagic acid, ellagitannins, and gallic acid (Ambigaipalan, De 
Camargo, & Shahidi, 2016; Elfalleh et al., 2011; Heber, 2011; Johanningsmeier & Harris, 
2011; Larrosa et al., 2010; Legua et al., 2012; Masci et al., 2016; Sreekumar, Sithul, 
Muraleedharan, Azeez, & Sreeharshan, 2014; Venkata, Prakash, & Prakash, 2011; R. 
Wang, Ding, Liu, Xiang, & Du, 2010). Several animal and human studies have shown 
that pomegranate juice and extracts demonstrate significant bioactive properties, 
including antioxidant and anti-inflammatory effects (Al-Kuraishy & Al-Gareeb, 2016; M. 
Aviram et al., 2000; Michael Aviram et al., 2004; BenSaad, Kim, Quah, Kim, & Shahimi, 
2017; Bishayee et al., 2011, 2013; Cano-Lamadrid et al., 2016; de Nigris et al., 2005; 
Husari et al., 2016; Kaplan et al., 2001; Larrosa et al., 2010; Matthaiou et al., 2014; 
Mertens-Talcott, Jilma-Stohlawetz, Rios, Hingorani, & Derendorf, 2006; Rosenblat, 
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Volkova, Coleman, & Aviram, 2006; Rozenberg, Howell, & Aviram, 2006; Seeram et al., 
2005). Pomegranate juice, extracts, and their bioactive constituents suppress 
inflammatory cell signaling, reduce expression of oxidation-sensitive genes and pro-
inflammatory cytokines in response to cellular stress, reduce blood biomarkers of 
inflammation and oxidative stress, and modulate endothelial nitric oxide synthase 
expression (Adams et al., 2006; L. G. Chen, Liu, Hsieh, Liao, & Wung, 2008; Ghavipour 
et al., 2016). 
Animal experiments in which rodents have been given pomegranate extracts or 
had pomegranate juiced added to their drinking water have demonstrated the 
neuroprotective effects of the pomegranate’s bioactive phytochemicals. The amount of 
juice consumed was similar, on a mg/kg basis, to a human dose of 1 to 2 cups of pure 
pomegranate juice. Initially, pomegranate’s neuroprotective propertied were 
demonstrated when the offspring of pomegranate-supplemented pregnant mice were 
protected from neonatal hypoxic-ischemic brain injury (Loren, Seeram, Schulman, & 
Holtzman, 2005). These results prompted experiments with APP transgenic mice, in 
which 6 months of consumption reduced Aβ plaques in the hippocampus and improved 
maze performance (Richard E Hartman et al., 2006). Later experiments suggested that the 
reduction in Aβ levels likely resulted from modulations in APP enzymatic processing, 
presumably leading to less production of Aβ and increased production of soluble APP-α 
(sAPPα, an endogenous neuroprotective peptide produced by α-secretase processing of 
APP). Another study showed that ellagic acid derived from pomegranate rinds inhibited 
β-secretase activity in vitro (Kwak et al., 2005). More recent mouse studies examining 
the consumption of pomegranate peel extract showed increased brain-derived 
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neurotrophic factor expression and reduced Aβ plaque density, AChE activity, lipid 
peroxidation, and pro-inflammatory cytokine expression (Morzelle et al., 2016). These 
results were similar to other APP transgenic mouse studies in which pomegranate juice 
supplementation improved learning and memory and reduced Aβ plaque deposition 
(Rojanathammanee, Puig, & Combs, 2013) and showed significant improvements in 
memory, learning, and locomotor function while reducing anxiety (Subash et al., 2015). 
Another recent mouse study showed that pomegranate supplementation protected against 
proton irradiation-induced anxiety (Dulcich & Hartman, 2013). Finally, pomegranate 
supplementation has been experimentally demonstrated to improve cognitive 
performance in humans after heart surgery (Ropacki, Patel, & Hartman, 2013) and with 
mild cognitive impairment (Bookheimer et al., 2013). 
Overall, this growing body of experimental evidence shows that the phenolic 
acids found in pomegranates may directly or indirectly provide significant behavioral and 
neuropathological protection against age-related disorders, including AD, by multiple 
mechanisms that work together to prevent establishment and progression of Aβ 
deposition and neurodegeneration. Interestingly, in vitro experiments show that isolated 
phytochemical components may not provide as much benefit as the whole juice, 
suggesting that the wide variety of phenolic acid isoforms present in the whole fruit may 
provide synergistic benefits (Seeram et al., 2005). One study even showed that the 
conjugated sucroses, fructoses, and glucoses found in pomegranates also have antioxidant 
properties (Rozenberg et al., 2006). Some recent studies have shown that bacteria in the 
gut can metabolize the large punicalagins into smaller anti-inflammatory molecules like 
urolithin-A that may have higher bioavailability (Espín, Larrosa, García-Conesa, & 
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Tomás-Barberán, 2013; Larrosa et al., 2010; Seeram et al., 2006; T. Yuan et al., 2016). 
These findings suggest that further comparative studies of isolated phytochemical 
metabolites may lead to increased understanding of their true mechanisms of action and 
the mediating role of microbiome metabolism. Finally, numerous other studies have 
shown pomegranate and its bioactive constituents to be anti-carcinogenic, antibacterial, 
anti-apoptotic, and protective for the cardiovascular system (Ahmed, El Morsy, & 
Ahmed, 2014; Al-Kuraishy & Al-Gareeb, 2016; M. Aviram et al., 2000; Michael Aviram 
et al., 2004; Braga et al., 2005; K. Cao et al., 2015; Chavez-Valdez, Martin, & 
Northington, 2012; de Nigris et al., 2005; Howell & Souza, 2013; Kaplan et al., 2001; 
Riaz & Khan, 2016; Rosenblat et al., 2006; Rozenberg et al., 2006; Seeram et al., 2005; 
Shafik & El Batsh, 2016; Syed, Chamcheu, Adhami, & Mukhtar, 2013; L. Wang, Li, Lin, 
Garcia, & Mulholland, 2013), suggesting that consumption of pomegranates and their 




Resveratrol is a stilbenoid polyphenol found in grapes and nuts that has been 
shown to induce Aβ clearance and decrease Aβ levels in vivo in part via intracellular 
proteasome-facilitated degradation of Aβ (Karuppagounder et al., 2009). Additionally, 
resveratrol modulates several Aβ-related cell-signaling pathways (Capiralla et al., 2012; 
Köbe et al., 2017; Porquet et al., 2014), which may explain the epidemiological evidence 
for a decreased risk of developing AD among elderly individuals who drink small to 
moderate amounts of wine. Experimental models of traumatic brain injury have 
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demonstrated that treatment with resveratrol immediately after traumatic brain injury 
reduces oxidative stress and even reduces lesion volume (Ates et al., 2007). These 
findings are supported by resveratrol’s neuroprotective effects in adult and neonatal 
rodent models of ischemic stroke (Wan et al., 2016; West, Atzeva, & Holtzman, 2007). 
 
Flavonoids 
The flavonoid class of polyphenols includes the flavans and pigment compounds like the 
anthocyanidins and anthoxanthins. 
 
Flavans 
 The flavan class of polyphenols includes flavanols such as the catechins, which 
are found in high concentration in tea leaves. Catechins and phenolic acids (e.g., tannins) 
make up about 25% of the tea leaf, which also contains psychoactive compounds (e.g., 
caffeine; see psychoactive alkaloid section). Tea has been used medicinally for centuries, 
likely because of these bioactive phytochemicals. Tea consumption is still very common 
globally, but epidemiological evidence correlating tea consumption with the risk of 
developing AD has been mixed. However, multiple lines of experimental evidence 
suggest that tea may protect against oxidative stress (I. C. Burckhardt et al., 2008; Yan 
Xu et al., 2010) and that some of tea’s compounds may protect various AD-related 
pathways. For example, a transgenic mouse study demonstrated that an extract of black 
tea polyphenols significantly reduced memory impairment, oxidative damage, Aβ burden, 
and apoptosis (Mathiyazahan, Justin Thenmozhi, & Manivasagam, 2015). 
Isolated catechins found in tea have been studied more in depth. Epigallocatechin-
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3-gallate (EGCG) is a well-characterized catechin found in tea that has been shown to 
decrease behavioral impairments, reduce Aβ production, and decrease y-secretase activity 
in transgenic mice (H. J. Lim et al., 2013). In another transgenic mouse study, EGCG 
treatment restored respiratory rates and membrane potential, reduced ROS production, 
and increased ATP levels by 50 to 85% in mitochondria isolated from the hippocampus, 
cortex, and striatum (Dragicevic et al., 2011). In addition to the neuroprotective effects of 
ECGC, a recent study of aging rats examined a tea extract rich in other catechins, but 
poor in ECGC. The data demonstrated improved learning and memory and reduced 
oxidative stress, suggesting that tea consumption is associated with multiple catechins 
having a synergistic neuroprotective effect above and beyond isolated tea catechins 
(Rodrigues et al., 2013). Overall, the phenolic acids and flavonoids found in tea offer 
multi-faceted neuroprotection from AD via multiple mechanisms. 
 
Anthocyanidins 
Anthocyanidins are water soluble pigments with potent with antioxidant and anti-
inflammatory properties found in high concentrations in fruits such as the blueberry 
(Giacalone et al., 2015; Malin et al., 2011; Nica Sousa, Teixeira, & Soares, 2014). Rodent 
models of AD have shown that a blueberry enriched diet significantly reduced learning 
and memory impairments mediated by excitotoxicity and oxidative stress, decreased 
neuronal loss, and inhibited AChE activity (Duffy et al., 2008; Papandreou et al., 2009; 
Williams et al., 2008). In a recent study, a single drink containing blueberry flavonoids 
was given to 8-10-year-old children 2 hours before a brief memory assay and was 
associated with overall improved delayed recall, but increased susceptibility to proactive 
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interference (Whyte & Williams, 2015). 
 
Anthoxanthins 
 Anthoxanthins are another class of flavonoid pigment that includes compounds 
such as the flavones and flavonols. Luteolin is a flavone found in the leaves and rinds of 
many plants, including celery, broccoli and citrus fruits that acts on multiple pathways 
associated with the development of AD. Reported effects in transgenic mice include 
decreases in both Aβ deposition and tau phosphorylation (which can ultimately lead to 
NFTs in humans). Other studies using rat models of AD suggest that luteolin protects 
against Aβ-induced cognitive impairment by regulating the cholinergic system, inhibiting 
oxidative stress, and prevented hippocampal cell death in a chemically-induced model of 
AD (H. Wang, Wang, Cheng, & Che, 2016; T.-X. Yu, Zhang, Guan, Wang, & Zhen, 
2015). Additionally, luteolin has been shown to reduce neuroinflammation and Aβ 
deposition following experimental traumatic brain injury in transgenic mice (Sawmiller et 
al., 2014). Finally, luteolin demonstrates significant antioxidant action, regulates 
phosphorylation (R. Liu et al., 2009; Zhou, Chen, Xiong, Li, & Qu, 2012), inhibits 
mitochondrial dysfunction induced by myocardial insult, protects BBB permeability in 
AD rodent models, reduces apoptosis in Parkinson’s disease rodent models, alleviates 
obesity-induced cognitive impairment in a rodent model of type-2 diabetes mellitus, and 
has anti-carcinogenic properties in an animal model of lung cancer (Guo, Li, Yu, & Chan, 
2013; Y. Liu et al., 2014; Pratheeshkumar et al., 2014; D. Yu, Li, Tian, Liu, & Shang, 
2015; J.-X. Zhang et al., 2017). Thus, like other polyphenols, luteolin seems to be readily 
available in the diet and may provide protection from age-related neuropathology from 
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several different angles. 
Flavonols such as fisetin, quercetin, myricetin, and kaempferol have also 
demonstrated bioactive properties of interest to aging and AD research. For example, 
fisetin, which is found in strawberries and other fruits and vegetables, enhanced cognitive 
performance and reduced inflammation in a rodent model of induced neurodegeneration 
(Prakash, Gopinath, & Sudhandiran, 2013). Fisetin’s affects appear to be in part 
attributable to increases in cAMP response element binding (CREB), which plays an 
important role in learning and memory mechanisms and has been shown to reduce Aβ 
plaque formation. Additionally, isolated preparations of quercetin and myricetin have 
been shown to reduce Aβ-related damage to muscarinic acetylcholine receptors (Hu, 
Ding, Zhou, & Xu, 2015; Ramezani, Darbandi, Khodagholi, & Hashemi, 2016). 
Kaempferol and quercetin are flavonols found in especially high concentrations in 
the leaves of the gingko biloba tree, which have been used medicinally for centuries due 
to their purported cognitive enhancing properties. In addition to kaempferol and 
quercetin, ginkgo biloba also contains terpenes such as ginkgolides and bilobalides (see 
section on ginkgolides and bilobalides). It has most often been studied experimentally 
using an extract known as EGb761, which has been standardized to 24% polyphenol / 6% 
terpene content, allowing relatively easy comparisons between experimental studies. 
Multiple clinical trials have shown that daily treatment with EGb761 for a period of 12-
24 weeks can provide mild cognitive improvements in elderly and demented patients 
(Herrschaft et al., 2012; Ihl, Tribanek, & Bachinskaya, 2012; Napryeyenko, Sonnik, & 
Tartakovsky, 2009). A study of several thousand non-demented elderly adults compared 
the effects of EGb761 to piracetam on cognitive functioning over a 20-year period. 
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Results indicated less cognitive decline in subjects taking EGb761 than those who 
reported regular use of piracetam (Amieva, Meillon, Helmer, Barberger-Gateau, & 
Dartigues, 2013). Another recent randomized, placebo-controlled trial of several hundred 
outpatients was conducted to demonstrate the efficacy and safety of EGb761 treatment 
for 24 weeks in patients with AD or vascular dementia. EGb76 treatment produced 
significant and clinically relevant improvements in cognition, psychopathology, 
functional measures, and quality of life for patients and caregivers. Importantly, no 
significant toxicities were observed (Herrschaft et al., 2012). However, in another 
randomized, placebo-controlled trial, adults aged 70 years or older who presented with 
initial memory complaints were administered EGb761 daily and followed for conversion 
to probable AD diagnoses. In these subjects, EGb761 did not reduce the risk of 
progression to AD compared with controls given a placebo (Schneider, 2012; Vellas et 
al., 2012). However, like many failed clinical trials of AD treatments, it is possible that 
the intervention was simply started too late, since neuropathology generally precedes the 
clinical symptoms by several years. 
Several animal and in vitro studies have demonstrated that EGb761 can modulate 
multiple pathways related to both brain function and neuroprotection. For example, 
EGb761 has been shown to increase dopaminergic transmission in the rat PFC 
(Yoshitake, Yoshitake, & Kehr, 2010), increase production of brain derived neurotrophic 
factor in aged rats (Belviranlı & Okudan, 2014), improve mitochondrial respiration in 
vitro (Tendi et al., 2002), and attenuate lipid peroxidation and superoxide free radical 
production in a mouse model of Parkinson’s disease (Rojas et al., 2008). In addition to its 
potent antioxidant properties, EGb761 also acts as an AChE inhibitor, so several studies 
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have compared its clinical effects to pharmaceutical AChE inhibitors. One study found 
that combined treatment with EGb761 and donepezil was superior to either compound 
alone and produced fewer side effects than mono-therapy with donepezil (Yancheva et 
al., 2009). Although AChE inhibitors have demonstrated mostly disappointing results in 
the treatment of AD, research into the efficacy of the extract persists because of its 
minimal side effect profile and other potential mechanisms of action (Weinmann, Roll, 
Schwarzbach, Vauth, & Willich, 2010). EGb761 has also been shown to reduce Aβ 
deposition, enhance CREB phosphorylation, and promote cell proliferation in the 
hippocampi of young and aged transgenic mice (Tchantchou, Xu, Wu, Christen, & Luo, 
2007). In another study, transgenic mice that were given EGb761 for 20 weeks via 
dietary supplementation demonstrated significantly improved cognitive function, 
attenuated loss of synaptic proteins, inhibition of caspase-1, and less inflammation via 
microglia-induced secretion of TNF-α and IL-1β (X. Liu et al., 2015). This pattern of 
results suggests that the phytochemicals in EGb761 act on AD pathology via multiple 
synergistic mechanisms, including antioxidant, anti-inflammatory, and anti-AChE 
pathways (Eckert, 2012; Müller, Heiser, & Leuner, 2012). 
Concerns about the bioavailability of phytochemicals like EGb761, such as their 
ability to cross the BBB, have led to recent investigations on the pharmacokinetics of 
these compounds. A rat study found that repeated oral administration of standard EGb761 
doses for 1 week led to as much as a 10x increase in the plasma concentration of its 
flavonols components, which were also found in the hippocampus, frontal cortex, 
striatum, and cerebellum (Rangel-Ordóñez, Nöldner, Schubert-Zsilavecz, & Wurglics, 
2010). Thus, although gingko biloba is generally not considered a dietary plant, the 
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available evidence suggests that readily available concentrated extracts may provide 




Terpenes are hydrocarbon compounds produced by plants (and some insects) that 
often have strong odors and an oily consistency. Terpenes of interest to aging and AD 
research include the ginkgolides and bilobalides (found in ginkgo biloba), huperzine A 
(found in Chinese club moss), and the phytocannabinoids (found in cannabis). 
 
Ginkgolides and Bilobalides 
As mentioned above, gingko biloba is often studied using EGb761, an extract that 
has been standardized to contain 24% polyphenols and 6% terpenes (the ginkgolides and 
bilobalides). Studies using EGb761 are discussed in more detail in the previous section, 
and it should be noted that its polyphenols and terpenes seem to act together in a 
synergistic fashion to provide its neuroprotective effects (Eckert, 2012; Müller et al., 
2012). However, at least one study suggests that ginkgolide J, one of its terpenoid 
components, provided similar protection from the detrimental effects of Aβ on long term 
potentiation as the whole extract (Vitolo et al., 2009). 
 
Huperzine A 
Huperzine A is a terpene alkaloid with AChE inhibiting properties found in the 
toothed clubmoss plant. It has been shown to promote neurogenesis in the rodent dentate 
27 
gyrus (T. Ma et al., 2013) and protect mitochondria against Aβ deposition by preserving 
membrane integrity and improving energy metabolism (Gao, Zheng, Yang, Tang, & 
Zhang, 2009). Both huperzine A and Huprine X, which is synthesized by combining 
components of huperzine A with a synthetic AChE inhibitor, improved learning and 
memory in a transgenic mouse model of AD (X. Ma & Gang, 2008; Ratia et al., 2013). 
However, recent clinical trials have yielded mixed results, and the low availability of 
toothed clubmoss, along with the relatively poor performance of pharmaceutical 
acetylcholinesterase inhibitors, has slowed progress (Rafii et al., 2011). 
 
Cannabinoids 
Cannabis is a plant with long history of both medicinal and recreational use. 
Cannabis contains a wide variety of terpenes, collectively known as phytocannabinoids, 
that bind with CB1 and CB2 cannabinoid receptors. CB1 receptors are expressed mainly 
in the cerebral cortex and are thought to be responsible for cannabis’ well-documented 
psychoactive effects. CB2 receptors are expressed mainly in the periphery and are 
thought to play a role in a variety of inflammatory processes. These compounds, 
including tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), have 
structural similarity to endogenous cannabinoid neurotransmitters such as anandamide 
and 2-AG, and are antioxidant, anti-inflammatory, and neuroprotective against 
excitotoxicity and acute brain damage (Haghani, Shabani, Javan, Motamedi, & 
Janahmadi, 2012; Harvey, Ohlsson, Mååg, Musgrave, & Smid, 2012). Additionally, 
phytocannabinoids have been demonstrated to enhance mitochondrial functioning (C. 
Cao et al., 2014) and stimulate neurogenesis within the embryonic and adult 
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hippocampus (Jiang et al., 2005; Wolf et al., 2010). 
Aging is associated with dysregulation of cannabinoid receptor expression 
(Bisogno & Di Marzo, 2010), and stimulation of cannabinoid receptors with synthetic 
cannabinoids has been shown to attenuate these effects (Marchalant et al., 2009; 
Marchalant, Cerbai, Brothers, & Wenk, 2008). A recent study demonstrated that THC 
restored cognitive performance in older mice, but, interestingly, the opposite effect was 
observed in younger mice (Bilkei-Gorzo et al., 2017). Several studies have suggested 
multiple mechanisms by which cannabinoids, including the phytocannabinoids found in 
cannabis, can also affect AD process. There is currently no conclusive epidemiological 
evidence on long-term cannabis users and a reduced incidence of AD, but multiple lines 
of experimental evidence suggest a possible protective effect. Although the relationship 
between cannabinoid receptors and AD pathogenesis remains unclear, cannabinoid 
receptor expression and the activity levels of enzymes that control endogenous 
cannabinoid concentrations change with the development of AD (Marchalant et al., 
2009). Postmortem studies of AD and Down syndrome brains reveal consistently 
elevated levels of CB2 expression, whereas CB1 receptors are often reduced (J. H. Lee et 
al., 2010; Solas, Francis, Franco, & Ramirez, 2013) (Benito et al., 2003; Núñez et al., 
2008; Tolón et al., 2009). These and other observations suggest that endogenous 
cannabinoids such as 2-AG mediate inflammatory and neuroprotective processes (X. 
Chen, Zhang, & Chen, 2011; Piro et al., 2012). 
A study of transgenic mice that also lacked CB1 receptors reported that despite a 
decrease in Aβ plaque load, significant learning and memory deficits persisted, 
suggesting that CB1 receptor deficiency can worsen AD-related cognitive deficits 
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independent of Aβ plaque load (Stumm et al., 2013). Another study showed that the rate 
of Aβ clearance across the BBB was doubled by stimulation of the endogenous 
cannabinoid 2-arachidonoylglycerol (2AG) via inhibition of endogenous cannabinoid-
degrading enzymes (Bachmeier, Beaulieu-Abdelahad, Mullan, & Paris, 2013; Bisogno & 
Di Marzo, 2010). Furthermore, another study demonstrated that treatment with a 
synthetic CB2 agonist reduced Aβ-induced memory loss (Wu et al., 2013), and in vitro 
data shows that THC inhibits Aβ aggregation via indirect interaction with Aβ peptides 
(Eubanks et al., 2006). Finally, studies of synthetic cannabinoids have shown them to 
ameliorate cognitive impairment and neurodegeneration in multiple models of Aβ-
induced neurotoxicity and neuroinflammation independent of antioxidant and/or 
psychoactive properties (R. Chen et al., 2012; Martín-Moreno et al., 2012; Martin-
Moreno et al., 2011). Thus, cannabinoids, including those found in cannabis, seem to act 
on age-related and AD-specific neuropathological processes through multiple pathways, 
suggesting a potential role for exogenous (e.g., phyto- or synthetic) cannabinoids in the 
prevention and/or treatment of AD. 
 
Organosulphurs 
 Garlic contains many aromatic sulfur-containing phytochemicals, including s-allyl 
cysteine (SAC) and di-allyl disulfide, collectively known as organosulfurs. Adding an 
aged garlic extract, SAC, or di-allyl-disulfide to the diets of transgenic mice has been 
shown to ameliorate cognitive deficits, reduce Aβ plaque formation, reduce abnormal tau 
build-up, and reduce oxidative damage (Asdaq, 2015; Chauhan, 2006; Colin-Gonzalez, 
Ali, Tunez, & Santamaria, 2015; Javed et al., 2011; Qu, Mossine, Cui, Sun, & Gu, 2016). 
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SAC has been shown to inhibit and reverse Aβ aggregation in vitro and in transgenic 
mice by binding directly to the Aβ peptide (Ray, Chauhan, & Lahiri, 2011). Another in 
vitro study examining the neuroprotective potential of SAC found reduced apoptosis that 
was not attributable to antioxidant activity, but rather to suppression of calpain proteins 
(Imai et al., 2014, 2016). The isolated components of SAC also appear to have AD-
related neuroprotective properties, and may produce a synergistic effect in combination 
with di-allyl-disulfide. Together, these findings suggest that garlic and its organosulfur 




Omega-3 fatty acids, such as α-linolenic acid, docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA), are found mainly in flax, nuts, algae, and certain fish. DHA 
and EPA make up about 15% of the human brain’s total fatty acids and 30-40% of its 
gray matter. Consuming omega-3 fatty acids can reduce inflammation, improve learning 
and memory, increase gray matter volume, and alter gut microbiota composition. DHA 
has been shown to protect against Aβ-induced neurotoxicity in transgenic mice and has 
demonstrated anti-inflammatory and anticancer properties (Calon et al., 2004; Lebbadi et 
al., 2011; Yuhai Zhao et al., 2011). In vitro studies have shown that DHA and EPA can 
reduce Aβ aggregation, increase production of neurotrophic substances, and decrease 
production of pro-inflammatory cytokines (Hjorth et al., 2013). Additionally, omega-3 
derivatives can promote α-secretase processing of APP, which prevents the production of 
Aβ and leads instead to the production of the neuroprotective peptide sAPPα (Yuhai Zhao 
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et al., 2011). A recent study of AD patients found that 24 weeks of omega-3 
supplementation produced increased levels of EPA and DHA in plasma and cerebrospinal 
fluid (CSF) that were inversely correlated with CSF levels of phosphorylated tau (Freund 
Levi et al., 2014). However, another recent study demonstrated that Aβ pathology may 
limit the ability of DHA to readily cross the BBB, which may explain why several 
clinical trials have yielded inconclusive or negative results, despite the high 
bioavailability of DHA (M. Burckhardt et al., 2016; Yassine et al., 2016). 
 
Phytovitamins  
Epidemiological evidence mentioned in Chapter 3 suggests a protective effect of 
dietary vitamins against the risk of developing AD, and experimental evidence with 
humans and rodents tends to support this idea. Tocopherols (isoforms of vitamin E) and 
folic acid (an isoform of vitamin B9) are found in several commonly consumed plants. A 
recent clinical trial of vitamin E supplementation in AD patients taking AChE inhibitors 
reported a 19% per year delay in clinical progression (Dysken et al., 2014), but recent 
clinical trials of vitamin E in isolation have yielded less promising results, suggesting that 
vitamin E may be better suited as a complementary therapy for AD (Farina et al., 2012). 
However, in a study of aged rats, vitamin E-supplementation improved age-related 
cognitive deficits (Takatsu, Owada, Abe, Nakano, & Urano, 2009), and several 
transgenic mouse studies have demonstrated beneficial AD-related effects of 
supplementing with vitamin E. For example, dietary administration of vitamin E to 
transgenic mice reduced Aβ deposition (Hashimoto et al., 2005) along with its associated 
oxidative stress and neuritic dystrophy (Zimmermann, Colciaghi, Cattabeni, & Di Luca, 
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2002), and it ameliorated behavioral impairments, oxidative stress, and injury-accelerated 
Aβ formation resulting from repetitive traumatic brain injury (Conte et al., 2004). 
Therefore, the data suggest that dietary tocopherols may protect the brain from Aβ 
deposition and its associated functional decline. 
Other studies have focused on B vitamins, because dietary deficiencies have been 
associated with cognitive decline and an increase in AD-related neuropathology. For 
example, a study of elderly individuals with a vitamin B deficiency found that reversing 
the deficiency with folic acid (an isoform of vitamin B9 found in many fruits and 
vegetables) improved cognitive function after 14 weeks (Cheng et al., 2016). A 
transgenic mouse study looked at the effects of dietary folic acid deficiency on 
neuropathology in transgenic mice and reported significant neurodegeneration within the 
hippocampus, although Aβ levels were not affected (Kruman  II et al., 2002). An in vitro 
study of folic acid deprivation demonstrated increased expression of the genes involved 
in encoding the γ- and β-secretases along with increased levels of Aβ (Fuso, Seminara, 
Cavallaro, D’Anselmi, & Scarpa, 2005). In a study of high dose B vitamin supplements 
given to healthy adult participants over 4-weeks, increased task-related functional brain 
activity (Barbey, 2016). However, a similar high dose combination of vitamins B6 and 
B12 was ineffective at slowing cognitive decline in individuals with mild to moderate 
AD, suggesting that vitamin B may be more effective as a preventive measure for AD 
than as an acute intervention for AD related cognitive decline (Aisen et al., 2008). Other 
trials of folic acid supplementation in humans have shown that its long-term consumption 
is associated with decreased plasma levels of Aβ and increased grey matter volume in the 
brain (Erickson et al., 2008; Flicker et al., 2008). These studies, along with data showing 
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the neuroprotective effects of folic acid on the developing nervous system and the anti-
oxidant properties of dietary tocopherols, suggest that consuming phytovitamins may 
offer neuroprotection from oxidative stress that contributes to increased Aβ deposition 





Although tea and coffee contain high levels of beneficial polyphenol compounds, 
the psychoactive alkaloid caffeine explains their global popularity. Caffeine functions as 
an insecticide in plants and as a psychostimulant in animals. Because its stimulant effects 
(resulting from its competitive inhibition of adenosine receptors in the brain) are not 
associated with the euphoria and addictive properties characterized by other 
psychostimulants (e.g., cocaine and amphetamines), caffeine has been used centuries 
throughout the globe as a general cognitive enhancer. Recent studies with animal models 
of AD have shown that caffeine consumption is associated with protection against 
oxidative stress, improved mitochondrial functioning and BBB permeability, increased 
expression of brain derived neurotrophic factor, and reduced Aβ deposition and 
associated cognitive deficits (C. Cao et al., 2009; Xuesong Chen et al., 2008; Dragicevic 
et al., 2012; Laurent et al., 2014; Prasanthi et al., 2010). One study compared pure 
caffeine to “crude” caffeine, which is derived from coffee during the decaffeination 
process and likely contains other compounds (e.g., phenolic acids). Both supplements had 
beneficial effects in a transgenic mouse model of AD, including neuroprotection from 
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Aβ-induced neuronal death via suppressed caspase-3 activity. However, crude caffeine 
was more effective in reducing learning and memory deficits, and only crude caffeine 
reduced hippocampal Aβ deposition, suggesting that “phyto”-caffeine may offer 
protection from AD-related processes above and beyond that produced by pure caffeine 
(Chu et al., 2012). Interestingly, “caffeinol” (a combination of caffeine and ethanol) has 
been shown to demonstrate potent synergistic neuroprotection in rodent models of stroke 
(Bednarski, Gasińska, Straszewski, Godek, & Tutka, 2015; Martin-Schild et al., 2009; X. 
Zhao et al., 2010). Caffeine’s mild stimulant effects may improve cognition, and it 
appears to offer multiple synergistic pathways of neuroprotection from AD pathology, 
including inhibition of Aβ aggregation and protection from neurologic insult. 
 
Nicotine 
Nicotine is another alkaloid that protects the tobacco plant from insect predators 
and produces psychostimulant effects in animals, primarily due to its agonist action at 
nicotinic acetylcholine receptors. Like caffeine, nicotine has a long history of human use 
at least partially due to its stimulant and cognitive enhancement properties. Although 
some previous studies have demonstrated in both humans and animals that nicotine may 
have potential neuroprotective effects on AD pathology, further research has 
demonstrated that smokers are at a significantly higher risk of developing AD via 
multiple pathways (N. T. Aggarwal et al., 2006; Durazzo, Mattsson, & Weiner, 2014; 
Huang, Dong, Zhang, Wu, & Liu, 2009). Chronic nicotine administration in transgenic 
mouse models of AD has been shown to increase levels of brain-derived neurotrophic 
factor and prevent long-term memory impairment induced by Aβ deposition (Alkadhi, 
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Alzoubi, Srivareerat, & Tran, 2011; Srivareerat, Tran, Salim, Aleisa, & Alkadhi, 2011). 
Possible mechanisms include activity at the nicotinic acetylcholine receptors, which 
results in decreased oxidative damage, Aβ deposition, and apoptosis. In addition to the 
potential cognitive enhancement, antioxidant, and anti-Aβ actions attributed to nicotine, 
its psychoactive metabolite, nornicotine, has been shown to inhibit Aβ aggregation by 
forming permanent covalent bonds with Aβ peptides (Kumar et al., 2011). These finding 
suggest that pharmaceutical treatment with nicotine may provide positive benefits in the 





The development of AD-related neuropathology and its associated behavioral 
deficits is related to the gradual accumulation of Aβ plaques and NFTs in the cortex over 
the lifespan. This causes increased oxidative stress and inflammation in the brain, leading 
to further Aβ deposition, neuronal degradation, and other downstream effects. A variety 
of acute or low-grade chronic neurological insults can accelerate this process, and current 
pharmacological treatment options appear to be only minimally beneficial. 
In the absence of effective pharmaceutical therapies for AD, focusing on lifestyle 
factors associated with reducing risk of developing AD appears to be the most effective 
preventive measure. The difficulty of demonstrating consistent beneficial effects of 
phytochemicals in humans is not surprising, given the similar failures of pharmacological 
interventions. Nevertheless, several lines of research demonstrate that long-term 
consumption of various phytochemicals may attenuate multiple neuropathological 
processes associated with the development of AD. The results of experimental data from 
animal studies and clinical trials, along with a growing body of epidemiological studies, 
lend credibility to the idea that bioactive phytochemicals can have beneficial effects via 
multiple mechanisms related to general brain aging, including regulation of the 
intestinal/gut microbiome and BBB permeability, modulation of neurotransmitter 
degradation and binding, anti-inflammatory and antioxidant effects, reduced 
susceptibility to excitotoxicity and apoptosis, stimulation of neurogenesis and long-term 
potentiation, and maintenance of proper mitochondrial function and other cellular 
processes related to learning and memory (Akaishi et al., 2008; Maher, 2009). 
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Additionally, bioactive phytochemicals have demonstrated beneficial effects on multiple 
AD-specific processes, including inhibition of Aβ production by modulating enzymatic 
processes and reducing Aβ deposition in the brain by decreasing aggregation and 
increasing clearance. 
Given that AD is progressive, insidious, and ultimately fatal disease effecting a 
significant portion of older individuals, delaying the onset of AD by even a slight margin 
would significantly impact its incidence. Mounting epidemiological and experimental 
evidence suggests that a lifetime of consuming an abundance of neuroprotective 
phytochemicals may provide significant protection from environmental and age-related 
insults that accelerate the progression of AD neuropathology (Bayram et al., 2012; Steele 
et al., 2007; Subash et al., 2015). Furthermore, diets containing a wide variety of 
bioactive phytochemicals from multiple plant sources may provide synergistic benefits 
over supplementing with isolated compounds (Berti et al., 2015; Uysal et al., 2013). 
Finally, chronic adherence to diets rich in diverse sources of bioactive dietary 
polyphenols may protect against neurodegenerative disorders such as AD, but may also 
confer additional health and age-related benefits.   
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